Method for producing microparticles containing poorly soluble drugs

The use of a mixed solvent system with specific co-solvents and microfluidic processing enhances the encapsulation of poorly soluble drugs in microparticles, addressing issues of low encapsulation and residual solvent, resulting in uniform and efficient microparticle production.

JP2024544146AActive Publication Date: 2024-11-28INVENTAGE LAB INC
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
JP2024528601
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-17
Filing Date
2022-11-17
Publication Date
2024-11-28
Estimated Expiration
2042-11-17

AI Technical Summary

Technical Problem

Existing methods for producing microparticles containing poorly soluble drugs face challenges such as low encapsulation rates, loss of drugs during solvent removal, and difficulty in maintaining uniformity and quality due to the use of single organic solvents with high boiling points and viscosity.

Method used

A method involving the use of a mixed solvent system comprising a first solvent (e.g., dichloromethane) and a co-solvent with specific properties (low density, polarity, and boiling point) to dissolve poorly soluble drugs and biodegradable polymers, followed by a microfluidic process to maintain laminar flow and enhance encapsulation, and subsequent solvent removal steps to minimize residual solvent.

Benefits of technology

The method achieves high encapsulation rates (>90%) of poorly soluble drugs, reduces residual solvent content, and ensures uniform, spherical microparticles with improved manufacturing efficiency and quality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544146000001
    Figure 2024544146000001
  • Figure 2024544146000002
    Figure 2024544146000002
  • Figure 2024544146000003
    Figure 2024544146000003
Patent Text Reader

Abstract

The present invention relates to a method for producing microparticles containing a poorly soluble drug and microparticles produced by such a method, which uses two or more types of organic solvents to produce microparticles that are uniform and of excellent quality, have a high encapsulation rate of the poorly soluble drug, and have a low amount of residual organic solvent.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing microparticles containing poorly soluble drugs. [Background technology]

[0002] In order to prepare microparticles or sustained-release preparations containing a poorly soluble drug, it is common to dissolve the poorly soluble drug together with a biodegradable polymer in an organic solvent and disperse it in an aqueous phase to prepare an emulsion. For example, a sustained-release preparation containing a poorly soluble drug can be prepared by preparing an O / W (oil in water) emulsion to form microparticles containing a poorly soluble drug, and then removing the organic solvent from the emulsion. However, in the process of preparing the emulsion to form the microparticles, it is important to thoroughly dissolve the poorly soluble drug and the biodegradable polymer in the oil phase solution, so that the poorly soluble drug does not escape into the aqueous phase solution and is lost, thereby increasing the encapsulation rate of the poorly soluble drug in the biodegradable polymer, and to prevent the poorly soluble drug from transferring to the aqueous phase and being lost in the process of removing the organic solvent after the formation of the microparticles. This depends on which organic solvent is selected, so the selection of the solvent is an important issue in the method of preparing microparticles containing a poorly soluble drug.

[0003] In the process of forming microparticles or preparing an emulsion for sustained release preparations, it is important to dissolve the biodegradable polymer as well as the drug component in the solvent, because the drug must be encapsulated in the biodegradable polymer to achieve sustained release of the drug. In general, for example, dichloromethane can be used as an organic solvent for dissolving the biodegradable polymer. However, some poorly soluble drugs have relatively low solubility in dichloromethane, so a large amount of solvent must be used to dissolve the poorly soluble drug in the dichloromethane solvent. However, if the amount of solvent used increases, the possibility of residual organic solvent remaining increases, and the poorly soluble drug is more likely to escape from the oil phase solution to the aqueous phase solution during the process of preparing the microparticles. This causes a problem of loss of the drug component in the microparticles and a low encapsulation rate of the drug in the biodegradable polymer.

[0004] Methods for producing such microparticles include, for example, methods using porous membranes, microfluidics using microchannels, emulsion methods, or spray drying methods.

[0005] In the method for preparing the microparticles, the viscosity of the oil phase solution containing the poorly soluble drug and the biodegradable polymer plays an important role in the preparation process, and it is important to select the type and content of the organic solvent to adjust the viscosity of the oil phase solution. However, when the content of the organic solvent is increased to adjust the viscosity, there is a problem that the poorly soluble drug is likely to be lost and the organic solvent is likely to remain, as described above.

[0006] In addition, since the method of removing the solvent from the microparticles differs depending on the properties of the solvent, the solvent used to prepare the oil phase solution may affect the encapsulation rate of the poorly soluble drug in the biodegradable polymer, the content of the residual organic solvent, and the economic efficiency of the manufacturing method, etc. Methods for removing the solvent from the microparticles include a solvent evaporation method and a solvent extraction method.

[0007] The solvent evaporation method is a method of removing a solvent by increasing the temperature to the boiling point of a volatile solvent having a relatively low boiling point and evaporating the solvent. This has the advantage of being a simple process and taking less time than the solvent extraction method, but due to the characteristics of the drug corresponding to the active ingredient of the microparticles, the drug may disappear together with the solvent due to the increase in temperature, resulting in a problem of a decrease in the encapsulation rate of the drug in the biodegradable polymer.

[0008] The solvent extraction method is a method of removing a non-volatile solvent having a relatively high boiling point from the microparticles by diffusing it into an external solvent due to the concentration difference. In order to prevent the drug from being extracted together with the solvent, the solvent extraction is performed at a low temperature, and a co-solvent such as ethyl acetate or ethanol is added to the external aqueous phase solution of the microparticles to efficiently perform the solvent extraction such as benzyl alcohol.

[0009] In an attempt to increase the solubility of poorly soluble drugs, methods have been studied that use benzyl alcohol as a solubilizing agent to improve solubility, but in this case, a solvent extraction method is used. That is, since benzyl alcohol has a high boiling point of 205.4°C, in order to effectively remove it, the benzyl alcohol must be removed using a solvent extraction method other than the solvent evaporation method. For example, a poorly soluble drug and a biodegradable polymer are dissolved in dichloromethane and benzyl alcohol to prepare an oil phase solution, and the oil phase solution is dispersed in an aqueous phase to form microparticles, after which the benzyl alcohol is removed using ethyl acetate or ethanol as an extraction solvent.

[0010] However, in the above-mentioned solvent extraction method, the extraction occurs according to a concentration gradient, so that the solvent is removed in proportion to the extraction time.

[0011] Therefore, it takes a lot of time to completely remove the remaining organic solvent.If a solvent such as benzyl alcohol is not completely removed and remains, the solvent acts as a solubilizer for the drug ingredient, and may cause a burst effect in which the drug is released from the microparticles all at once, departing from the release mechanism of the biodegradable polymer, which should be released slowly, making it difficult to control the release.

[0012] As described above, the solvent extraction method has the disadvantages of being more complicated in process and taking a longer production time than the solvent evaporation method.

[0013] Therefore, in a method for producing microparticles containing poorly soluble drugs, there is a need to develop an economical and efficient production method that can dissolve the poorly soluble drug well, increase the encapsulation rate of the drug in the biodegradable polymer, increase the convenience of production through a simple production method, and produce uniform microparticles. [Prior art documents] [Patent documents]

[0014] [Patent Document 1] KR10-2005-0093236A1 Summary of the Invention [Problem to be solved by the invention]

[0015] It is an object of the present invention to provide a method for producing microparticles containing poorly soluble drugs.

[0016] Another object of the present invention is to provide a production method which uses two or more types of organic solvents when dissolving a poorly soluble drug, and which has uniform and excellent quality, a high encapsulation rate of the poorly soluble drug, and can easily reduce the amount of residual organic solvent.

[0017] Another object of the present invention is to provide a method for producing microparticles which can reduce the viscosity or density of the oil phase solution by dissolving a poorly soluble drug and a biodegradable polymer in an organic solvent using a small amount of organic solvent, can maintain a laminar flow in a microchannel when producing microparticles by a microfluidic method, and has a high encapsulation rate of a poorly soluble drug while the produced microparticles are homogeneous and of excellent quality. [Means for solving the problem]

[0018] In order to achieve the above-mentioned object, the present invention relates to a method for producing microparticles containing a poorly soluble drug, which includes the steps of 1) dissolving a poorly soluble drug and a biodegradable polymer in a mixed solvent containing two or more organic solvents to produce an oil phase solution, 2) dissolving a surfactant in water to produce an aqueous phase solution, and 3) producing microparticles using the oil phase solution and the aqueous phase solution.

[0019] The mixed solvent may include a first solvent and a co-solvent, and the first solvent may be dichloromethane.

[0020] The co-solvent has a density of 1.3 g / cm 3 or less, polarity index is 3 or less, boiling point is 50°C or less, water solubility is 2 20 ~8 20 g / 100g water.

[0021] The first solvent and the co-solvent are contained in a weight ratio of 1:0.5 to 1:10.

[0022] The poorly soluble drugs include naltrexone, donepezil, finasteride, aripiprazole, olanzapine, palonosetron, minocycline, memantine, alendronate, deoxycholate, risedronate, etc. e), Ibandronate, Zoledronate, Liraglutide, Exenetide, Lanreotide, Octreotide, Deslorelin, Leuprorelin, Goserelin, Triptorelin, or Dutasteride.

[0023] The poorly soluble drug and the mixed solvent in step 1) can be mixed in a weight ratio of 1:7 to 1:30.

[0024] The poorly soluble drug and the biodegradable polymer in step 1) are contained in a weight ratio of 1:0.5 to 1:10.

[0025] The biodegradable polymer can be selected from the group consisting of polylactides, polylactic acids, polylactide-co-glycolides, polylactic-co-glycolic acids, polyphosphazenes, polyiminocarbonates, polyphosphoesters, polyanhydrides, polyorthoesters, polycaprolactones, polyhydroxyvalerates, polyhydroxybutyrates, polyamino acids, and combinations thereof.

[0026] The surfactant may be selected from the group consisting of polyethylene glycol sorbitan monooleate, sorbitan oleate, sodium lauryl sulfate, polyvinyl alcohol (PVA), methylcellulose, polyvinylpyrrolidone, lecithin, gelatin, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, sodium stearate, ester amines, linear diamines, fatty amines, and combinations thereof.

[0027] In the step 3), microparticles can be produced using an oil phase solution and an aqueous phase solution by an emulsion method, a porous membrane method, a spray drying method, or a microfluid method.

[0028] The method may further include a step of removing residual organic solvent from the microparticles produced in step 3).

[0029] The step of removing the residual organic solvent may involve placing the microparticles containing the residual organic solvent in an aqueous phase solution and stirring to remove the residual organic solvent.

[0030] The stirring process may include a first stirring step at 10°C to 20°C and 200 to 400 rpm for 30 minutes to 2 hours, a second stirring step at 25°C to 35°C and 200 to 400 rpm for 30 minutes to 2 hours, and a third stirring step at 45°C to 55°C and 200 to 400 rpm for 30 minutes to 2 hours.

[0031] Microparticles containing a poorly soluble drug according to another embodiment of the present invention can be prepared by the above-mentioned preparation method.

[0032] The microparticles may have an encapsulation rate of the poorly soluble drug of 90% or more, and may have a smooth surface and a perfectly spherical shape. Effect of the Invention

[0033] The present invention uses two or more organic solvents when dissolving a poorly soluble drug, and can easily produce a drug with uniform and excellent quality, a high encapsulation rate of the poorly soluble drug, and a low amount of residual organic solvent.

[0034] In addition, the viscosity or density of the oil phase solution can be reduced by dissolving the poorly soluble drug and the biodegradable polymer in a small amount of organic solvent. When microparticles are produced by a microfluidic method, a laminar flow can be maintained in the microchannel, and the produced microparticles have a high encapsulation rate of the poorly soluble drug while being homogeneous and of excellent quality. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0035] The present invention relates to a method for producing microparticles containing a poorly soluble drug, comprising the steps of: 1) dissolving a poorly soluble drug and a biodegradable polymer in a mixed solvent containing two or more types of organic solvents to produce an oil phase solution; 2) dissolving a surfactant in water to produce an aqueous phase solution; and 3) producing microparticles using the oil phase solution and the aqueous phase solution. EXAMPLES

[0036] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will now be described in detail with reference to the accompanying drawings, in which: FIG. 1 is a block diagram of a semiconductor memory device according to an embodiment of the present invention;

[0037] In order for microparticles containing poorly soluble drugs to have an excellent therapeutic effect, the poorly soluble drug must be well soluble and contained in the microparticles at a high ratio, the amount of residual organic solvent unrelated to the efficacy of the drug must be small, and the size of the microparticles must be uniform.

[0038] Some poorly soluble drugs dissolve to some extent in water at room temperature in the form of a salt (e.g., the hydrochloride salt of the poorly soluble drug naltrexone has a water solubility of 100 mg / mL at 25°C), but in the free base form, they are hardly soluble in water and do not completely dissolve even in organic solutions. Organic solvents for producing microparticles having excellent properties while containing such poorly soluble drugs in the free base form must be able to dissolve the poorly soluble drug together with the biodegradable polymer, prevent the poorly soluble drug from being lost in the aqueous phase solution, and be easily removable after the microparticles are produced.

[0039] Therefore, the selection of an organic solvent with suitable properties is important.

[0040] In addition, the choice of solvent is also important for economically and efficiently producing uniformly sized microparticles. For example, in the case of microfluidic methods, laminar flow of the aqueous and oil phases must be maintained within the microchannel to produce uniformly sized microparticles.

[0041] Even with the same fluid, the Reynolds number (Re) changes depending on the viscosity, density, flow rate, channel length, etc. of the fluid in the microchannel. When the Reynolds number is 2300 or less, laminar flow is formed, and when the Reynolds number is 4000 or more, turbulent flow is formed. When an oil phase solution is injected into a microchannel through which an aqueous phase solution flows, turbulent flow applies non-uniform forces to the oil phase solution particles (i.e., the dispersed phase), which may hinder the formation of oil phase solution particles of a certain size and inhibit the quality and production yield of microparticles. Therefore, in order to form a laminar flow, the velocity of the fluid must be reduced or the viscosity and / or density of the oil phase solution must be reduced.

[0042] The method of reducing the velocity of the fluid has an advantage that a laminar flow can be easily formed by changing the production conditions, but the reduced velocity may result in a decrease in productivity.

[0043] Therefore, a suitable solvent must be used to reduce the viscosity and density of the oil phase solution so that laminar flow can be maintained while still ensuring productivity.

[0044] In addition, when a porous membrane is used to produce microparticles, the viscosity of the oil phase solution is important because the oil phase solution must easily pass through the pores of the membrane.

[0045] In the emulsion method, which is another method, the viscosity of the oil phase solution is also important because if the viscosity is excessively high, dispersion of the oil phase solution by external energy becomes unfavorable.

[0046] In the case of the spray drying method, the droplets are dispersed and the solvent is evaporated by wind to produce microparticles, so it is important to use a highly volatile solvent. In producing microparticles, the selection of the solvent is also important in order to reduce the solvent evaporation energy.

[0047] When manufacturing microparticles, if an excess amount of solvent is used to achieve sufficient viscosity, the microfluidic method can maintain laminar flow and facilitate the production of microparticles, but it consumes a lot of energy and time to remove the excess solvent, and it is difficult to quickly remove the organic solvent from the oil phase solution particles (dispersed phase), so there is a high possibility that the drug will transfer to the aqueous phase solution and be lost.

[0048] Therefore, the present invention relates to a method for producing microparticles that can solve the above problems, increase the encapsulation rate of poorly soluble drugs, and efficiently remove residual organic solvents in the microparticles.

[0049] Specifically, the method for producing microparticles containing a poorly soluble drug of the present invention can include the steps of 1) dissolving the poorly soluble drug and a biodegradable polymer in a mixed solvent containing two or more organic solvents to produce an oil phase solution, 2) dissolving a surfactant in water to produce an aqueous phase solution, and 3) producing microparticles using the oil phase solution and the aqueous phase solution.

[0050] The mixed solvent for dissolving the poorly soluble drug and the biodegradable polymer includes a first solvent and a co-solvent, and the first solvent may be dichloromethane.

[0051] Generally, to prepare microparticles using an organic solvent, a solvent in which the drug and the biodegradable polymer are easily soluble is used, and a commonly used solvent is dichloromethane.

[0052] However, even when an organic solvent such as dichloromethane is used, some poorly soluble drugs have low solubility. To solve this problem, the present invention is characterized in that a co-solvent is included in addition to the first solvent, thereby increasing the solubility of poorly soluble drugs and subsequently making them easily removable when the organic solvent is removed.

[0053] The co-solvent has a density of 1.3 g / cm 3 or less, polarity index is 3 or less, boiling point is 50°C or less, water solubility is 2 20 ~8 20 g / 100g water. Specifically, the co-solvent may have a density of 1.3 g / cm 3 Less than 0.5-1.3g / cm 3 and 0.5 to 1.0 g / cm 3 and 0.6 to 0.9 g / cm 3 may be also possible.

[0054] The polarity is 3 or less, is 1-3, or may be 2-3.

[0055] The boiling point is 50°C or less, may be 30°C to 50°C, or may be 30°C to 40°C.

[0056] In addition, the water solubility is 2 20 ~8 20 g / 100g water, 3 20 ~8 20 g / 100g water, 5 20 ~820 g / 100g water.

[0057] When a co-solvent that satisfies the above density conditions, polarity conditions, boiling point conditions, or water solubility is used in combination with the first solvent, it serves to increase the solubility of the poorly soluble drug by assisting the first solvent. When a co-solvent is used to remove residual organic solvent in the prepared microparticles, the co-solvent is removed before the first solvent, dichloromethane, preventing the drug from escaping into the aqueous phase solution and increasing the concentration or viscosity of the biodegradable polymer present in the oil phase solution, thereby strengthening the bond between the poorly soluble drug and the biodegradable polymer and increasing the encapsulation rate of the drug in the biodegradable polymer.

[0058] In addition, since the boiling point of the co-solvent is 50° C. or less, the properties of the biodegradable polymer do not change even when heated during the solvent removal process, and the release pattern of the microparticles does not change. In addition, since the co-solvent has a low density, even a small amount of the co-solvent can reduce the viscosity or density of the oil phase solution, thereby making it possible to produce uniform and high-quality microparticles.

[0059] Such a co-solvent may in particular be a volatile organic solvent or a volatile non-polar organic solvent.

[0060] The volatile organic solvent can be selected from the group consisting of acetone, acetonitrile, benzene, butyl alcohol carbon disulfide, carbon tetrachloride, chloroform, cyclohexane, 1,1-dichloroethane, dimethoxyethane, ethanol, diethyl ether, ethyl acetate, heptane, hexane, methanol, methyl acetate, methyl t-butyl ether, pentane, propyl alcohol, tetrahydrofuran, and combinations thereof.

[0061] Also, the volatile non-polar organic solvent can be selected from the group consisting of cyclohexane, pentane, hexane, heptane, carbon tetrachloride, carbon disulfide, benzene, diethyl ether, methyl t-butyl ether, tetrahydrofuran, ethyl acetate, methyl acetate, chloroform, and combinations thereof.

[0062] When the co-solvent is used as a mixed solvent with the first solvent, even if the co-solvent does not dissolve poorly soluble drugs or biodegradable polymers well by itself, when it acts together with the first solvent, dichloromethane, it can increase the solubility of the poorly soluble drugs or biodegradable polymers and reduce the viscosity of the oil phase solution.

[0063] As described above, the co-solvent may have the property of volatilizing or evaporating before dichloromethane. In general, the transfer of the drug to the aqueous solution occurs on the surface of the microparticles that are not completely dried, and as the organic solvent remaining inside the microparticles is removed, the internal viscosity increases and hardening occurs, which reduces the reactivity with the aqueous solution and reduces the probability of the drug transferring to the aqueous solution.

[0064] Therefore, when a cosolvent having the above-mentioned properties is used, the cosolvent is removed before the primary solvent, dichloromethane, preventing the drug from escaping into the aqueous phase solution, increasing the concentration or viscosity of the biodegradable polymer present in the oil phase solution, and strengthening the bond between the poorly soluble drug and the biodegradable polymer, thereby increasing the encapsulation rate of the drug within the biodegradable polymer.

[0065] In order to produce uniform and high-quality microparticles, the viscosity or density of the oil phase solution containing the microparticles, the biodegradable polymer, and the organic solvent is important. The co-solvent has a lower density than the primary solvent, so even if a small amount is used, it can reduce the density of the oil phase solution. When producing microparticles by a microfluidic method, the oil phase solution and the aqueous phase solution maintain laminar flow in the microchannel, making it possible to produce uniform and high-quality microparticles and to easily remove the residual organic solvent.

[0066] The co-solvent may preferably be diethyl ether or pentane, but is not limited to the above examples. Any co-solvent that satisfies the conditions of the co-solvent, increases the solubility of the poorly soluble drug together with the first solvent, and has the property of volatilizing or vaporizing before the first solvent can be used without limitation.

[0067] In step 1), the weight ratio of the poorly soluble drug and the mixed solvent may be, but is not limited to, about 1:7 to about 1:30, about 1:7 to about 1:29, about 1:7 to about 1:28, about 1:7 to about 1:27, about 1:7 to about 1:26, about 1:7 to about 1:25, about 1:7 to about 1:24, about 1:7 to about 1:23, about 1:7 to about 1:22, about 1:7 to about 1:21, about 1:7 to about 1:20, about 1:7 to about 1:19, about 1:7 to about 1:18, about 1:7 to about 1:17, about 1:7 to about 1:16, or about 1:7 to about 1:15.

[0068] In step 1), the weight ratio of the poorly soluble drug and the biodegradable polymer may be, but is not limited to, about 1:0.5 to about 1:10, about 1:0.5 to about 1:9, about 1:0.5 to about 1:8, about 1:0.5 to about 1:7, about 1:0.5 to about 1:6, or about 1:1 to about 1:5.

[0069] In step 1), the weight ratio of the co-solvent to the primary solvent may be, but is not limited to, about 1:0.5 to about 1:10, about 1:0.5 to about 1:9, about 1:0.5 to about 1:8, about 1:0.5 to about 1:7, or about 1:0.5 to about 1:6.

[0070] Preferably, the weight ratio of the poorly soluble drug and the mixed solvent is 1:15 to 1:20, and the weight ratio of the co-solvent and the first solvent may be 1:0.5 to 1:6, but is not limited to the above examples. The poorly soluble drug can be well dissolved within the above range, and if the mixed solvent is contained below the above range, the poorly soluble drug may recrystallize and precipitate, and the viscosity may become too high, which may cause difficulties in filtration and preparation. If an excessive amount of solvent is used, there is no major problem in preparation, but the absolute amount of organic solvent used may increase, causing the poorly soluble drug to be lost in the aqueous phase solution, making it difficult to remove the residual organic solvent.

[0071] The content of the biodegradable polymer in the organic solvent may be, but is not limited to, about 5 to about 50% by weight, about 5 to about 40% by weight, about 5 to about 30% by weight, about 5 to about 20% by weight, or about 5 to about 10% by weight based on the amount of the biodegradable polymer (e.g., polylactide-co-glycolide copolymer) used. The total amount of the organic solvent used can be changed depending on the viscosity of the biodegradable polymer and the amount of the poorly soluble drug used. If the amount of the poorly soluble drug is large or the viscosity of the biodegradable polymer is high, the amount of the organic solvent used can be increased to reduce the total concentration. However, when the biodegradable polymer is dissolved in the organic solvent within the above range, it is within a range in which the convenience of manufacturing microparticles is achieved and the removal of the residual organic solvent is also easy.

[0072] The poorly soluble drugs include naltrexone, donepezil, finasteride, aripiprazole, olanzapine, palonosetron, minocycline, memantine, alendronate, deoxycholate, risedronate, etc. e), Ibandronate, Zoledronate, Liraglutide, Exenetide, Lanreotide, Octreotide, Deslorelin, Leuprorelin, Goserelin, Triptorelin, or Dutasteride.

[0073] Naltrexone is also known as N-Cyclopropyl-methylnoroxymorphone, N-Cyclopropylmethyl-14-hydroxydihydro-morphinone, 17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one, EN-1639A, or UM-792.

[0074] The naltrexone may be a compound having the following formula:

[0075] [ka]

[0076] Donepezil is also known as 1-Benzyl-4-[(5,6-dimethoxy-1-indanon-2-YL)methyl]piperidine.

[0077] The donepezil may be a compound represented by the following chemical formula:

[0078] [ka]

[0079] Finasteride is also known as N-(1,1-dimethylethyl)-3-oxo-(5α,17β)-4-azaandrost-1-ene-17-carboxamide.

[0080] The finasteride may be a compound having the following chemical formula:

[0081] [ka]

[0082] The poorly soluble drug of the present invention may be a solvate, stereoisomer, prodrug, metabolite (e.g., 6β-naltrexol), derivative (e.g., naloxone), free base, or a combination thereof of the poorly soluble drug.

[0083] The stereoisomers refer to compounds that have the same molecular formula and the same connection method of the constituent atoms, but have different spatial arrangements between the atoms. The solvates refer to compounds solvated in an organic or inorganic solvent. The solvates are, for example, hydrates. The stereoisomers may be partial diastereomers or enantiomers. The prodrugs may be compounds that are converted into target compounds in vivo after administration of the compounds. The metabolites may be compounds that are produced by metabolic processes in vivo. The derivatives refer to compounds obtained by replacing part of the structure of a poorly soluble drug with other atoms or atomic groups.

[0084] The biodegradable polymer may be selected from the group consisting of polylactides, polylactic acids, polylactide-co-glycolides, polylactic-co-glycolic acids, polyphosphazenes, polyiminocarbonates, polyphosphoesters, polyanhydrides, polyorthoesters, polycaprolactones, polyhydroxyvalerates, polyhydroxybutyrates, polyamino acids, and combinations thereof, but is not limited to the above examples.

[0085] As an example, the molar ratio of glycolide to lactide in polylactide-co-glycolide may be about 60:40 to about 90:10, about 60:40 to about 85:15, about 60:40 to about 80:20, about 60:40 to about 75:25, about 65:35 to about 90:10, about 70:30 to about 90:10, about 75:25 to about 90:10, about 65:35 to about 85:15, or about 70:30 to about 80:20, but is not limited to the above examples. Preferably, the molar ratio of glycolide to lactide in polylactide-co-glycolide may be about 75:25.

[0086] The biodegradable polymer may include one or more polylactides and one or more polylactide-co-glycolides. In the present invention, the biodegradable polymer may include, for example, a combination of two polylactides, one polylactide and one polylactide-co-glycolide, two polylactide-co-glycolides, three polylactides, two polylactides and one polylactide-co-glycolide, one polylactide and two polylactide-co-glycolides, and in particular, one polylactide and one polylactide-co-glycolide, or two polylactide-co-glycolides, but is not limited thereto.

[0087] The biodegradable polymer can include two or more types of polylactide-co-glycolide.

[0088] The aqueous phase solution may include water and a surfactant, and the surfactant may be any surfactant that can assist the oil phase solution in forming stable microparticles.

[0089] Specifically, the surfactant may be one or more selected from the group consisting of nonionic surfactants, anionic surfactants, cationic surfactants, and combinations thereof. For example, the surfactant may be any one or more selected from the group consisting of polyethylene glycol sorbitan monooleate, sorbitan oleate, sodium lauryl sulfate, polyvinyl alcohol (PVA), methylcellulose, polyvinylpyrrolidone, lecithin, gelatin, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, sodium stearate, esteramines, linear diamines, fatty amines, and combinations thereof, but is not limited thereto.

[0090] The content of the surfactant contained in the aqueous phase solution may be, but is not limited to, 0.1 to 1.0% (w / v), 0.2 to 0.8% (w / v), 0.25 to 0.7% (w / v), 0.4 to 0.6% (w / v), 0.4 to 0.5% (w / v), 0.5 to 0.6% (w / v), 0.1 to 0.3% (w / v), 0.2 to 0.3% (w / v), or 0.25 to 0.3% (w / v). For example, the aqueous phase solution containing a surfactant may be, but is not limited to, a 0.5% (w / v) PVA solution.

[0091] The viscosity of the oil phase solution in step 1) is in a range where the viscosity of the fluid (unit: cP; centipoise) is such that the fluid maintains a laminar flow state in the microchannel. The viscosity of the fluid can be measured with a Brookfield Model LVT viscometer, and can be measured at 80 to 100 rpm using an LV01 or LV02 spindle. The viscosity of the oil phase solution is measured at 25°C. When the measurement is started with the viscometer, a certain value of viscosity is measured after the measurement solution is stabilized, and generally, the stabilization of the solution proceeds in about 1 minute.

[0092] The oil phase solution in step 1) may have a viscosity or density that allows it to maintain a laminar flow state together with the aqueous phase solution in step 2). Specifically, the oil phase solution may have a viscosity or density that allows the fluid in the microchannel to maintain a laminar flow state when the oil phase solution is injected into the aqueous phase solution flowing in the microchannel. For example, the oil phase solution may have a viscosity or density that allows the Reynolds number of the fluid flowing in the microchannel to satisfy 2,300 or less.

[0093] In the step 3), microparticles can be produced using an oil phase solution and an aqueous phase solution by an emulsion method, a porous membrane method, a spray drying method, or a microfluid method.

[0094] Specifically, the process for producing microparticles by the microfluidic method can include the steps of: a) injecting an oil phase solution into a linear microchannel; b) injecting an aqueous phase solution into the microchannel on both sides or one side; and c) collecting the microparticles.

[0095] The step a) is to inject an oil phase solution into a linear microchannel to allow it to flow, and the step b) is to inject an aqueous phase solution into a microchannel on one or both sides formed to form an intersection with the linear microchannel to allow it to flow, i.e., the oil phase solution flows along the linear microchannel, and the aqueous phase solution flows along a microchannel that forms an intersection with the linear microchannel on one or both sides based on the linear microchannel, and can meet the flow of the oil phase solution.

[0096] In addition, in order to make the flow of the aqueous phase solution that forms an intersection with the flow of the oil phase solution flow at a faster flow rate than the flow of the oil phase solution injected into a linear microchannel, it is possible to make the aqueous phase solution flow under higher pressure conditions.

[0097] As described above, by making the flow rates of the oil phase solution and the aqueous phase solution different and making the flow rate of the aqueous phase solution faster than that of the oil phase solution, the aqueous phase solution having a relatively faster flow rate compresses the oil phase solution at the point where the oil phase solution flow meets the aqueous phase solution flow. At this time, the biodegradable polymer and poorly soluble drug in the oil phase solution generate spherical microparticles due to the repulsive force between the oil phase solution and the aqueous phase solution, and the spherical microparticles can be formed in a form in which the drug is evenly distributed on the spherical biodegradable polymer.

[0098] The preparation of microparticles by the microfluid method is a method of forming microparticles of a certain size by introducing an oil phase solution in which a poorly soluble drug, an organic solvent, and a biodegradable polymer are dissolved, together with an aqueous phase solution, into a microchannel, and thus preparing microparticles in the aqueous phase solution. The thus-formed micro-particles are stabilized by a surfactant in the aqueous phase solution, and the organic solvent inside the formed particles is evaporated or volatilized depending on the drying conditions, thereby removing the organic solvent inside the particles, thereby forming microparticles.

[0099] The emulsion method is a method in which an oil phase solution in which a poorly soluble drug, an organic solvent, and a biodegradable polymer are dissolved is mixed with an aqueous phase solution containing a surfactant, and then external energy (ultrasonic waves, high-speed rotational force, etc.) is applied to the mixture to cause the oil phase solution to form microparticles in the aqueous phase solution. The microparticles formed by the emulsion method are formed by removing the organic solvent from the particles as the organic solvent inside the particles evaporates or volatilizes depending on the drying conditions.

[0100] The porous membrane method is a method for producing microparticles by flowing an oil phase solution (dispersed phase) in which a poorly soluble drug, an organic solvent, and a biodegradable polymer are dissolved onto one side of a porous membrane with micropores, and flowing an aqueous phase solution (continuous phase) containing a surfactant onto the opposite side of the porous membrane, thereby cutting the oil phase solution with the flow of the aqueous phase solution.

[0101] The spray drying method is a method for producing microparticles by spraying an oil phase solution in which a poorly soluble drug, an organic solvent, and a biodegradable polymer are dissolved, without using an aqueous phase solution, with a spray dryer while blowing in heated air. The oil phase solution is finely sprayed to form microparticles, and the organic solvent inside the particles is evaporated or volatilized by the heated air, removing the solvent, forming microparticles.

[0102] Specific examples of the emulsion method and spray drying method are described in, for example, the literature [Koerner, J. (2019). Harnessing Dendritic Cells for Poly (D, L-lactide-co-glycolide) Microspheres (PLGA MS) - Mediated Anti-tumor Therapy. Frontiers] and the literature [Wang, Y (2016). Manufacturing Techniques and Surface Engineering of Polymer Based Nanoparticles for Targeted Drug Delivery to Cancer. Nanomaterials 6 (2), 26], but are not limited thereto.

[0103] Microparticles containing a poorly soluble drug according to another embodiment of the present invention are microparticles prepared by the above-mentioned preparation method.

[0104] The encapsulation rate of the poorly soluble drug in the microparticles may be about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%.

[0105] The microparticles are also called microspheres, and can refer to particles that can contain a poorly soluble drug as an active ingredient.

[0106] The median particle size (D50) of the microparticles may be about 30 μm to about 65 μm, about 30 μm to about 60 μm, about 30 μm to about 55 μm, about 30 μm to about 50 μm, about 35 μm to about 65 μm, about 40 μm to about 65 μm, about 45 μm to about 65 μm, about 35 μm to about 60 μm, about 40 μm to about 55 μm, or about 45 μm to about 50 μm.

[0107] In one embodiment, the microparticles may have a particle size distribution within the range of ±5 μm, ±7 μm, ±10 μm, ±12 μm, or ±15 μm based on the median particle size.

[0108] Furthermore, the microparticles may be such that 60% by weight or more, 65% by weight or more, 70% by weight or more, 75% by weight or more, 80% by weight or more, 85% by weight or more, 90% by weight or more, 95% by weight or more, or 99% by weight or more of the microparticles are present within such particle size distribution range based on the total microparticles.

[0109] [Experimental Example 1] Comparison of solubility by combination of dichloromethane and diethyl ether In order to compare the solubility of poorly soluble drugs depending on the type and combination of solvents, 0.5 g of the poorly soluble drug free base form naltrexone (Mallinckrodt; hereafter the same) was dissolved in the same total amount of organic solvent (7.0 g) with 1.0 g of biodegradable polymer (Corbion; PDLG7504 (ester type); hereafter the same) and mixed as shown in Table 1 below, and the dissolution of naltrexone and the biodegradable polymer was observed with the naked eye at room temperature. At this time, a transparent state in which no crystals or particles were visible to the naked eye was determined to be completely dissolved.

[0110] [Table 1]

[0111] If dichloromethane is used in excess, naltrexone can be dissolved, but the total amount of solvent used increases, which may cause problems such as residual organic solvents as described above. To avoid such problems, dichloromethane can be used alone as in Comparative Example 1, and the amount of dichloromethane used can be minimized to dissolve naltrexone, but recrystallization occurs, which is presumed to occur when naltrexone precipitates as crystals in a saturated solution due to pressure changes caused by compressed air and solvent volatilization when the oil phase solution is sprayed through a module together with the aqueous phase solution. In addition, in Comparative Example 2, in which diethyl ether was used alone as an organic solvent, not only naltrexone but also the biodegradable polymer did not dissolve at all. In contrast, in Examples 1 and 2, in which diethyl ether was mixed as a co-solvent with the first solvent dichloromethane, naltrexone and the biodegradable polymer were completely dissolved, the solubility was much higher than when each solvent was used alone, and no recrystallization occurred.

[0112] This is because the use of diethyl ether, which has poor solubility for naltrexone and biodegradable polymers, as a co-solvent affects the arrangement of the naltrexone molecules and dichloromethane, the first solvent, thereby increasing the solubility of naltrexone and the biodegradable polymers.

[0113] According to the experimental results, when dichloromethane or diethyl ether is used alone, neither naltrexone nor the biodegradable polymer dissolves, but when diethyl ether is used in combination with dichloromethane as a co-solvent, the solubility of naltrexone and the biodegradable polymer is increased.

[0114] As described above, it was confirmed that when dichloromethane and diethyl ether were used together, naltrexone and the biodegradable polymer could be completely dissolved even with a small amount of solvent.

[0115] Therefore, when microparticles are prepared using the mixed solvent as in Examples 1 and 2, the loss of naltrexone can be reduced, the encapsulation rate can be increased, the amount of organic solvent used can be reduced, and the residual organic solvent can be effectively removed.

[0116] Further experiments were then carried out to confirm this effect.

[0117] [Experimental Example 2] Comparative experiment of encapsulation rate, residual organic solvent and dissolution of naltrexone microparticles by solvent (1) Preparation of Microparticles Containing Naltrexone Microparticles for use in the experiments were produced as described below, and the contents of the components used in producing the microparticles are summarized in Table 2.

[0118] [Example 3] 0.5 g of naltrexone in free base form and 1.0 g of DL-lactide / glycolide copolymer were mixed and dissolved in 10.0 g of dichloromethane and 2.3 g of diethyl ether. The mixed oil phase solution was applied to a microchannel, respectively, to fabricate microparticles at the intersection of the oil phase solution and the aqueous phase solution, which were collected above the aqueous phase solution (10° C.). The aqueous phase solution was a 0.5% (w / v) PVA solution (0.5% (v / v) PVA mixed in water).

[0119] The organic solvent was removed from the prepared microparticles by stirring at 10° C. for 1 hour, 30° C. for 1 hour, and 50° C. for 1 hour. The prepared microparticles were filtered and then freeze-dried to complete the preparation of dried microparticles.

[0120] [Example 4] The same preparation as in Example 3 was carried out, except that 8.0 g of dichloromethane and 2.0 g of diethyl ether were mixed.

[0121] [Comparative Example 3] The same preparation as in Example 3 was carried out, except that 8.0 g of dichloromethane was mixed without diethyl ether.

[0122] [Comparative Example 4] The same preparation as in Example 3 was carried out, except that 12.3 g of dichloromethane was mixed without diethyl ether.

[0123] [Table 2]

[0124] (2) Comparison of encapsulation rate, residual organic solvent, and precipitation depending on the use of co-solvent and the amount of organic solvent The solubility, encapsulation rate, and residual organic solvent were evaluated for the microparticles produced in Experimental Example 2.(1). The presence or absence of dissolution was confirmed by visually checking for precipitation, and the encapsulation rate was measured using high-performance liquid chromatography (HPLC). The residual organic solvent was analyzed by gas chromatogram (GC). The results are shown in Table 3.

[0125] [Table 3]

[0126] When comparing Comparative Example 3 and Comparative Example 4, since naltrexone is poorly soluble in dichloromethane, if the amount of dichloromethane is insufficient, the naltrexone dissolved in the organic solvent during the preparation of the oil phase solution is precipitated by recrystallization, and as a result, microparticles cannot be prepared. When comparing Comparative Example 4 with Examples 3 and 4, it was confirmed that the encapsulation rate increased by about 6% when diethyl ether was used as a co-solvent compared to when dichloromethane was used alone, and the amount of residual organic solvent of dichloromethane was also reduced, and the amount of residual organic solvent of the entire mixture was also reduced.

[0127] According to the above results, the use of diethyl ether, which has a boiling point lower than that of dichloromethane, has the effect of increasing the encapsulation rate. This is because as diethyl ether evaporates at a lower temperature than dichloromethane, the concentration of naltrexone and biodegradable polymer in the microparticles increases, increasing the viscosity of the oil phase solution present in the microparticles, thereby maintaining the bond between naltrexone and the biodegradable polymer stronger.

[0128] [Experimental Example 3] Comparative experiment of encapsulation rate, residual organic solvent, and dissolution of naltrexone microparticles depending on the mixing ratio of solvents (1) Preparation of Microparticles Containing Naltrexone Microparticles for use in the experiments were produced as described below, and the contents of the components used in producing the microparticles are summarized in Table 4.

[0129] [Example 5] 0.5g of naltrexone and 1.0g of DL-lactide / glycolide copolymer were mixed and dissolved in 6.0g of dichloromethane and 2.0g of diethyl ether. The mixed oil phase solution was applied to the microchannel respectively to prepare microparticles at the intersection of the oil phase solution and the aqueous phase solution, which were collected on the aqueous phase solution (10°C). The aqueous phase solution was a 0.5% (w / v) PVA solution. The prepared microparticles were stirred at 10°C for 1 hour, 30°C for 1 hour, and 50°C for 1 hour to remove the organic solvent. The prepared microparticles were obtained by sieving and then freeze-dried to complete the preparation of dried microparticles.

[0130] [Example 6] The microparticles were prepared as in Example 5, except that the organic solvent was removed by stirring at 10° C. for 1.5 hours, 30° C. for 1.5 hours, and 50° C. for 1.5 hours.

[0131] [Example 7] This was produced in the same manner as in Example 5, except that 3.0 g of diethyl ether was added.

[0132] [Table 4]

[0133] (2) Comparison of encapsulation rate, residual organic solvent, and dissolution rate of naltrexone microparticles depending on the mixing ratio of solvents

[0134] [Table 5]

[0135] When comparing Example 5 and Example 6, it was confirmed that the encapsulation rate decreased as the organic solvent removal time was increased, and this result confirmed that there was no significant difference in the residual amount of organic solvent as the organic solvent removal time was increased.

[0136] Comparing Example 5 and Example 7, it was confirmed that the ratio of dichloromethane and diethyl ether used as organic solvents affects the encapsulation rate. It can be confirmed that the encapsulation rate of naltrexone in the microparticles increases as the ratio of diethyl ether to dichloromethane increases.

[0137] [Experimental Example 4] Experiments using different types of organic solvents as co-solvents The encapsulation rate of microparticles and the content of residual organic solvents were evaluated when other cosolvents were used in addition to diethyl ether. Microparticles were produced in the same manner as in Example 3 of Experimental Example 2. The properties of usable cosolvents, including diethyl ether, are summarized in Table 6, and examples using various cosolvents are summarized in Table 7.

[0138] [Table 6]

[0139] (1) Preparation of donepezil-containing microparticles [Example 8] 0.98264 g of donepezil, 1.0 g of DL-lactide / glycolide copolymer, and 3.0 g of lactide copolymer were mixed and dissolved in 22.667 g of dichloromethane. The mixed oil phase solution was applied to the microchannel, respectively, to prepare microparticles at the intersection of the oil phase solution and the aqueous phase solution, which were collected on the aqueous phase solution (10°C). The aqueous phase solution was a 0.25% (w / v) PVA solution. The prepared microparticles were stirred at 10°C for 1 hour, 30°C for 1 hour, and 40°C for 3 hours to remove the organic solvent. The prepared microparticles were obtained by sieving and then freeze-dried to complete the preparation of dried microparticles.

[0140] [Example 9] 0.98264 g of donepezil, 1.0 g of DL-lactide / glycolide copolymer, and 3.0 g of lactide copolymer were dissolved in a mixture of 6.0 g of dichloromethane and 4.5 g of diethyl ether, and the preparation method was the same as in Example 8.

[0141] [Example 10] 0.98264 g of donepezil, 1.0 g of DL-lactide / glycolide copolymer, and 3.0 g of lactide copolymer were dissolved in a mixture of 8.0 g of dichloromethane and 3.0 g of pentane, and the preparation method was the same as in Example 8.

[0142] [Example 11] 0.98264 g of donepezil, 1.0 g of DL-lactide / glycolide copolymer, and 3.0 g of lactide copolymer were dissolved in a mixture of 6.0 g of dichloromethane and 4.5 g of methyl t-butyl ether. The preparation method was the same as in Example 8.

[0143] [Table 7]

[0144] (2) Comparison of encapsulation rate and residual organic solvent in donepezil microparticles depending on the type of cosolvent

[0145] [Table 8]

[0146] When comparing Example 8 and Example 9, the amount of dichloromethane used was reduced by using the co-solvent diethyl ether, and the residual solvent content of dichloromethane was lower in Example 9, which used diethyl ether under the same drying conditions.

[0147] In addition, in the case of Example 10, the residual solvent of pentane used as a co-solvent was measured to be very high. This is because although the boiling point of pentane is lower than that of diethyl ether, the solubility of pentane in water is poor, and therefore pentane could not be removed to the outside through water.

[0148] In the case of Example 11, the boiling point of methyl t-butyl ether is higher than that of pentane, and its solubility in water is higher than that of pentane, so it is believed that the residual solvent was removed. However, it was confirmed that the boiling point was higher than the final drying temperature, so the solvent was not sufficiently removed, resulting in the surface of the microparticles being uneven and holes being formed.

[0149] [Experimental Example 5] Evaluation of increasing the ratio of polymer in the oil phase solution by using a co-solvent When preparing the oil phase solution, the use of a co-solvent reduces the viscosity, making it possible to dissolve a higher concentration of polymer than when dichloromethane is used as a sole solvent.

[0150] (1) Preparation of donepezil-containing microparticles

[0151] [Table 9]

[0152] [Example 12] The same production method as in Example 8 was used, and 1.0 g of DL-lactide / glycolide copolymer and 3.0 g of lactide copolymer were mixed and dissolved in 22.667 g of dichloromethane.

[0153] [Example 13] 0.98264 g of donepezil, 1.0 g of DL-lactide / glycolide copolymer, and 3.0 g of lactide copolymer were mixed and dissolved in 6.0 g of dichloromethane, and the preparation method was the same as in Example 8.

[0154] [Example 14] 0.98264 g of donepezil, 1.0 g of DL-lactide / glycolide copolymer, and 3.0 g of lactide copolymer were mixed and dissolved in 10.5 g of dichloromethane, and the preparation method was the same as in Example 8.

[0155] [Example 15] 0.98264 g of donepezil, 1.0 g of DL-lactide / glycolide copolymer, and 3.0 g of lactide copolymer were mixed and dissolved in 6.0 g of dichloromethane and 4.5 g of diethyl ether, and the preparation method was the same as in Example 8.

[0156] [Example 16] 0.98264 g of donepezil, 1.0 g of DL-lactide / glycolide copolymer, and 3.0 g of lactide copolymer were dissolved in a mixture of 4.0 g of dichloromethane and 3.0 g of diethyl ether, and the preparation method was the same as in Example 8.

[0157] (2) Comparison of the viscosity of the oil phase solution depending on the ratio of co-solvents and confirmation of manufacturability

[0158] [Table 10]

[0159] Compared with Example 8, the viscosity of Example 12, which is a placebo solution without dissolving the main ingredient, is similar, which means that the main ingredient does not have a significant effect on the viscosity.

[0160] In addition, it was confirmed from Examples 13 and 14 that it is impossible to prepare a high-concentration oil phase solution having a solid content ratio of more than 30% by using a single solvent of dichloromethane.

[0161] However, in the case of Examples 15 and 16, in which diethyl ether was used as a co-solvent, the solid content ratio exceeded 30%, but the viscosity was lower than that of the single solvent group of dichloromethane with the same solid content ratio, confirming that microparticles could be produced without problems.

[0162] Depending on the viscosity or density of the organic solution used for producing the microparticles, the degree to which uniform microparticles can be produced, the degree to which the production time of the microparticles can be shortened, and the degree to which the residual organic solvent can be removed efficiently were evaluated, thereby evaluating the ease of producing the microparticles.

[0163] From the above description, a person skilled in the art to which the present invention pertains will understand that the present invention can be embodied in other specific forms without changing its technical concept or essential features. In this regard, it should be understood that the above-described embodiments are illustrative in all respects and are not limiting. The scope of the present invention should be interpreted as including all modifications and variations derived from the meaning and scope of the claims below, rather than the above detailed description, and the equivalent concepts thereof. [Industrial Applicability]

[0164] The present invention relates to a method for producing microparticles containing poorly soluble drugs.

[0165] This invention was supported by the following national research and development programs:

[0166] [Project unique number]1465031634 [Assignment number] HI20C0936 [Department name] Ministry of Health and Welfare [Name of issue management (specialized) organization] Korea Health Industry Promotion Agency [Research Project Name] Biohealth Investment Infrastructure Collaborative R&D [Research title] Development of long-acting injectables for the treatment of opioid and alcohol dependence using controlled and optimized manufacturing technology [Contribution rate] 1 / 1 [Name of project execution organization] Inventage Lab [Research period] 2022.01.01~2022.12.31

Claims

1. 1) preparing an oil phase solution by dissolving a poorly soluble drug and a biodegradable polymer in a mixed solvent containing two or more organic solvents; 2) dissolving a surfactant in water to produce an aqueous phase solution; 3) producing microparticles using the oil phase solution and the aqueous phase solution. A method for producing microparticles containing poorly soluble drugs.

2. the mixed solvent comprises a first solvent and a co-solvent; The first solvent is dichloromethane; A method for producing microparticles containing the poorly soluble drug according to claim 1.

3. The co-solvent has a density of 1.3 g / cm 3 Below is the A method for producing microparticles containing the poorly soluble drug according to claim 2.

4. The co-solvent has a polarity index of 3 or less. A method for producing microparticles containing the poorly soluble drug according to claim 2.

5. The co-solvent has a boiling point of 50° C. or less. A method for producing microparticles containing the poorly soluble drug according to claim 2.

6. The co-solvent has a water solubility of 2 20 ~8 20 g / 100g water, A method for producing microparticles containing the poorly soluble drug according to claim 2.

7. The first solvent and the co-solvent are included in a weight ratio of 1:0.5 to 1:10; A method for producing microparticles containing the poorly soluble drug according to claim 2.

8. The poorly soluble drugs include naltrexone, donepezil, finasteride, aripiprazole, olanzapine, palonosetron, minocycline, memantine, alendronate, deoxycholate, risedronate, and the like. ate, Ibandronate, Zoledronate, Liraglutide, Exenatide, Lanreotide, Octreotide, Deslorelin, Leuprorelin, Goserelin, Triptorelin, or Dutasteride, A method for producing microparticles containing the poorly soluble drug according to claim 1.

9. The poorly soluble drug and the mixed solvent in step 1) are mixed in a weight ratio of 1:7 to 1:30; A method for producing microparticles containing the poorly soluble drug according to claim 1.

10. The poorly soluble drug and the biodegradable polymer in step 1) are contained in a weight ratio of 1:0.5 to 1:10; A method for producing microparticles containing the poorly soluble drug according to claim 1.

11. The biodegradable polymer is selected from the group consisting of polylactides, polylactic acids, polylactide-co-glycolides, polylactic-co-glycolic acids, polyphosphazenes, polyiminocarbonates, polyphosphoesters, polyanhydrides, polyorthoesters, polycaprolactones, polyhydroxyvalerates, polyhydroxybutyrates, polyamino acids, and combinations thereof; A method for producing microparticles containing the poorly soluble drug according to claim 1.

12. The surfactant is selected from the group consisting of polyethylene glycol sorbitan monooleate, sorbitan oleate, sodium lauryl sulfate, polyvinyl alcohol (PVA), methylcellulose, polyvinylpyrrolidone, lecithin, gelatin, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, sodium stearate, ester amines, linear diamines, fatty amines, and combinations thereof. A method for producing microparticles containing the poorly soluble drug according to claim 1.

13. The step 3) comprises producing microparticles by an emulsion method, a porous membrane method, a spray drying method or a microfluidic method using the oil phase solution and the aqueous phase solution; A method for producing microparticles containing the poorly soluble drug according to claim 1.

14. The method further includes removing residual organic solvent from the microparticles produced in step 3). A method for producing microparticles containing the poorly soluble drug according to claim 1.

15. The step of removing the residual organic solvent comprises: The microparticles containing the residual organic solvent are placed in an aqueous phase solution and stirred to remove the residual organic solvent. A method for producing microparticles containing the poorly soluble drug according to claim 14.

16. The stirring step includes a first stirring step at 10° C. to 20° C. and 200 to 400 rpm for 30 minutes to 2 hours; A second stirring step at 25° C. to 35° C. and 200 to 400 rpm for 30 minutes to 2 hours; and third stirring at 45°C to 55°C and 200 to 400 rpm for 30 minutes to 2 hours. A method for producing microparticles containing the poorly soluble drug according to claim 15.

17. Produced by the method for producing microparticles according to any one of claims 1 to 16. Microparticles containing poorly soluble drugs.

18. The encapsulation rate of poorly soluble drugs is 90% or more, and the surface is smooth and the shape is perfectly spherical. A microparticle comprising the poorly soluble drug of claim 17.

Citation Information

Patent Citations

  • Method for manufacturing sustained release microsphere by solvent flow evaporation method

    EP2327397A2

  • Macromolecular microparticles for sustained drug release and method for producing the same

    JP2006508959A

  • Method for producing sustained-release microspheres by solvent-alternating evaporation

    JP2012501321A

  • Finasteride-containing microparticles and their manufacturing method

    JP2019534900A

  • Method for producing biodegradable microspheres with improved safety and storage stability

    JP2020521805A